Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer

Lung Cancer

Volumn 64, Issue 1, 2009, Pages 51-59

  Traynor, Anne M ^a   Schiller, Joan H ^b   Stabile, Laura P ^c   Kolesar, Jill M ^a   Eickhoff, Jens C ^a   Dacic, Sanja ^d   Hoang, Tien ^a   Dubey, Sarita ^e   Marcotte, Sarah M ^a   Siegfried, Jill M ^c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b University of Texas   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Epidermal growth factor receptor; Estrogen receptor; Hormonal treatment; Non small cell lung cancer; Sex

Indexed keywords

EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR BETA; FULVESTRANT; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEPHARITIS; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ESTRADIOL; FEMALE; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PILOT PROJECTS; POSTMENOPAUSE; PROGNOSIS; QUINAZOLINES; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 61449089509     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.07.002     Document Type: Article

References (63)

1. American Cancer Society. Cancer Facts and Figures 2005 (2005), American Cancer Society, Atlanta
2. Patel J.D. Lung cancer in women. J Clin Oncol 23 (2005) 3212-3218
3. Fu J.B., Kau T.Y., Severson R.K., and Kalemkerian G.P. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 127 (2005) 768-777
4. Ferguson M., Skosey C., and Hoffman P.C. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8 (1990) 1402-1407
5. Radzikowska E., Glaz P., and Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 13 (2002) 1087-1093
6. Risch H.A., Howe G.R., Jain M., Burch J.D., Holowaty E.J., Miller A.B., et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138 (1993) 281-293
7. Henschke C.I., and Miettinen O.S. Women's susceptibility to tobacco carcinogens. Lung Cancer 43 (2004) 1-5
8. Bach P.B., Kattan M.W., Thornquist M.D., Kris M.G., Tate R.C., Barnett M.J., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 95 (2003) 470-478
9. Bain C., Feskanich D., Speizer F.E., Thun M., Hertzmark E., Rosner B.A., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (2004) 826-834
10. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L., Luketich J.D., et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 92 (2000) 24-33
11. Mollerup S., Ryberg D., Hewer A., Phillips D.H., and Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59 (1999) 3317-3320
12. Dresler C.M., Fratelli C., Babb J., Everley L., Evans A.A., and Clapper M.L. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30 (2000) 153-160
13. Han W., Pentecost B.T., Pietropaolo R.L., Fasco M.J., and Spivack S.D. Estrogen receptor α increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells. Mol Carcinog 44 (2005) 202-211
14. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., and Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
15. Schwartz A.G., Wenzlaff A.S., Prysak G.M., Murphy V., Cote M.L., Brooks S.C., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
16. Fasco M.J., Hurteau G.J., and Spivack S.D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188 (2002) 125-140
17. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
18. Massaro D., Clerch L.B., and Massaro G.D. Estrogen receptor-α regulated pulmonary alveolar loss and regeneration in female mice: morphometric and gene expression studies. Am J Physiol Lung Cell Mol Physiol 293 (2007) L222-L228
19. Kirsch E.A., Yuhanna I.S., Chen Z., German Z., Sherman T.S., and Shaul P.W. Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells. Am J Respir Cell Mol Biol 20 (1999) 658-666
20. Omoto Y., Kobayashi Y., Nishida K., Tsuchiya E., Eguchi H., Nakagawa K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285 (2001) 340-347
21. Patrone C., Cassel T.N., Pettersson K., Piao Y.-S., Cheng G., Ciana P., et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 23 (2003) 8542-8552
22. Spivack S.D., Hurteau G.J., Fasco M.J., and Kaminsky L.S. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 9 (2003) 6002-6011
23. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., and Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65 (2005) 1459-1470
24. Jones S.E. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor. Seminars Oncol 30 5 Suppl. 16 (2003) 14-20
25. Xing D., Feng W., Miller A.P., Weathington N.M., Chen Y.F., Novak L., et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol 292 (2007) H2607-H2612
26. Hershberger P.A., Vasquez A.C., Kanterwicz B., Land S., Siegfried J.M., and Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 (2005) 1598-1605
27. Skov B.G., Fischer B.M., and Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59 (2008) 88-94
28. Wu C.T., Chang Y.L., Shih J.Y., and Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130 (2005) 979-986
29. Schwartz A.G., Prysak G.M., Murphy V., Lonardo F., Pass H., Schwartz J., et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 11 (2005) 7280-7287
30. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11 (2005) 5084-5089
31. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsch V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
32. Uramoto H., and Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br J Cancer 96 (2007) 857-863
33. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.-Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
34. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
35. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
36. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., DiMaria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
37. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
38. Li T., Ling Y.H., Goldman I.D., and Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13 (2007) 3413-3422
39. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P.D., Hart L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (2007) 4743-4750
40. Chinnaiyan P., Huang S., Vallabhaneni G., Armstrong E., Varambally S., Tomlins S.A., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65 (2005) 3328-3335
41. Marquez-Garban D.C., Chen H.W., Fishbein M.C., Goodglick L., and Pietras R.J. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72 (2007) 135-143
42. Pietras R.J., Marquez D.C., Chen H.W., Tsai E., Weinberg O., and Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70 (2005) 372-381
43. Boerner J.L., Gibson M.A., Fox E.M., Posner E.D., Parsons S.J., Silva C.M., et al. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol 19 (2005) 2660-2670
44. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17 (2003) 309-317
45. Robertson J.F.R. Fulvestrant (Faslodex) how to make a good drug better. Oncologist 12 (2007) 774-784
46. DeFriend D.J., Howell A., Nicholson R.I., Anderson E., Dowsett M., Mansel R.E., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54 (1994) 408-414
47. Zhang W., Stabile L.P., Keohavong P., Romkes M., Grandis J.R., Traynor A.M., et al. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol 1 (2006) 635-647
48. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
49. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., et al. Fulvestrant, formerly ICI 182 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
50. Socinski M.A., Novello S., Brahmer, Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 650-656
51. Gatzemeier U., Blumenschein G., Fosella F., Simantov R., Elting J., Bigwood D., et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24 Suppl. (2006) 364s [Abstract 7002]
52. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., DeMarinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
53. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
54. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
55. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
56. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
57. Nelson K.G., Takahashi T., Bossert N.L., Walmer D.K., and McLachlan J.A. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci U S A 88 (1991) 21-25
58. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor. GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16 (2002) 70-84
59. Pietras R.J., and Marquez-Garban D.C. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 13 (2007) 4672-4676
60. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (2003) 1032-1044
61. McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142 (2001) 2776-2788
62. Nicholson S., Wright C., Sainsbury J.R., Halcrow P., Kelly P., Angus B., et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 37 (1990) 811-814
63. Garon E.B., Sadeghi S., Kabbinavar F.F., Reckamp K.L., Marquez-Garban D.C., Stabile L.P., et al. Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 Suppl. (2008) 713s [Abstract 19091]